Article

Punctal plug tested as glaucoma treatment

Ocular Therapeutix has begun a feasibility study of a punctal plug delivering sustained-release travoprost (Travatan and Travatan Z, Alcon; Travo-Z, MicroLabs) to treat glaucoma.

Bedford, MA-Ocular Therapeutix has begun a feasibility study of a punctal plug delivering sustained-release travoprost (Travatan and Travatan Z, Alcon; Travo-Z, MicroLabs) to treat glaucoma.

As many as 20 patients with documented ocular hypertension or open-angle glaucoma will be enrolled at Singapore National Eye Center and the National University Hospital in Singapore. Primary endpoints will include IOP reduction from baseline and 30-day plug retention. This trial will be the first in a series, with later studies extending the length of travoprost delivery for several months.

“Our initial patients are showing significant drops in IOP by day 3, which is very promising,” said Shamira Perera, MD, principal investigator at the Singapore National Eye Center. “Additionally, the product is very easy to use and has not caused any discomfort upon insertion or during the retention period for any of our patients.”

The plugs use the company’s proprietary polyethylene glycol hydrogel technology to release the drug in a sustained fashion. At the end of the treatment period, the plug begins to degrade and exits the nasolacrimal system without needing to be removed by a physician. Each plug contains a visualization agent so that retention can be monitored throughout treatment.

“Positive results from this study will establish efficacy of our resorbable travoprost-loaded punctum plug technology, providing a stepping stone for advancements of this product with longer-term therapies,” said Amar Sawhney, PhD, president and chief executive officer of Ocular Therapeutix.

For more articles in this issue of Ophthalmology Times eReport, click here.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
Patricia Buehler, MD, MPH, founder and CEO of Osheru, talks about the Ziplyft device for noninvasive blepharoplasty at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Bonnie An Henderson, MD, on leveraging artificial intelligence in cataract refractive surgery
(Image credit: Ophthalmology Times) ASCRS 2025: Gregory Moloney, FRANZO, FRCSC, on rotational stability
Sheng Lim, MD, FRCOphth, discusses the CONCEPT study, which compared standalone cataract surgery to cataract surgery with ECP, at the 2025 ASCRS Annual Meeting.
(Image credit: Ophthalmology Times) ASCRS 2025: Steven J. Dell, MD, reports 24-month outcomes for shape-changing IOL
© 2025 MJH Life Sciences

All rights reserved.